DRW Securities’s Biogen BIIB Stock Holding History

DRW Securities’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-1,000	Closed	-$240K	–	67
2017 Q2	$240K	Buy	+1,000	New	+$264K	0.04%	54

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DRW Securities's BIIB Position: Q1 2026 in Review

DRW Securities reduced its Biogen (BIIB) stake by 32% in Q1 2026, selling an estimated $114K and leaving 1,335 shares worth $244K. The position accounts for ﹤0.01% of the portfolio, ranked #1002.

DRW Securities first reported a position in BIIB in Q2 2014 and has held it in 11 quarters since. The position peaked at $9.99M in Q2 2014. 1,003 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

DRW Securities held 1,335 shares of Biogen worth $244K as of Q1 2026.
DRW Securities sold 620 Biogen shares in Q1 2026, an estimated $114K.
Biogen made up ﹤0.01% of DRW Securities's portfolio in Q1 2026, its #1002 holding.
DRW Securities first reported a position in Biogen in Q2 2014 and has held it in 11 quarters since.
DRW Securities's Biogen position peaked at $9.99M in Q2 2014.
1,003 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on DRW Securities's 13F filing for Q1 2026, filed 13 May 2026.